Call Us 080-41656200 (Mon-Sat: 10AM-8PM)
Free Shipping above Rs. 1499
Cash On Delivery*

New targeted therapies for breast cancer

 

Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

 

Check Your Delivery Options

 
Rs. 2,675

Availability: In stock

 
  • Product Description
 

Breast cancer is the most common cancer in women worldwide. Understanding the biology of this tumor is a prerequisite for selecting an appropriate treatment. Cell cycle alterations are seen in many cancers such as breast cancer. Newly popular targeted agents in breast cancer have been reported such as cyclin dependent kinase inhibitors (CDKIs) which are agents inhibiting the function of cyclin dependent kinases (CDKs) as well as Notch, Wnt, SHH (Sonic hedgehog) which have recently been reported as a novel therapeutic target in breast cancer. They are categorized as selective and non-selective inhibitors of CDK. CDKIs have been tried as monotherapy and combination therapy. Palbocyclib is now a promising CDKI used in breast cancer. Nowadays palbocyclib is designed for a phase III trial for estrogen receptor (ER) positive breast cancer after showing favorable results in progression free survival in a phase II trial. The tumor microenvironment is increasingly recognized as a significant factor in cancer treatment response. The tumor microenvironment is considered as a target for combination therapy of breast cancer.

Product Specifications
SKU :COC55052
AuthorArmel Herve Nwabo Kamdje
LanguageEnglish
BindingPaperback
Number of Pages80
Publishing Year2014-05-12T00:00:00.000
ISBN9783659543395
Edition1 st
Book TypePharmacology
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
Product First Available On ClickOnCare.com2015-06-08 00:00:00